Cabrellis Pharmaceuticals Raises $27.5M

San Diego-based Cabrellis Pharmaceuticals, which is developing treatments for cancer, said Monday that it has raised $27.5M in a Series A funding round. Funding came from Domain Associates, Forward Ventures, Lilly Ventures, Novo A/S, ProQuest Investments, RBC Capital Partners, RiverVest Venture Partners, and S.R. One, Limited. Cabrellis said it would use the funding to advanced development of a third-generation anthracycline, currently in Phase II clinical testing. Cabrellis is a spinout of Conforma Therapeutics. More information »